Detail akcie Axsome Therapeutics online

Business Summary: Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, Solriamfetol, AXS-12 and AXS-14. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Axsome Therapeutics Inc revenues increased 67% to $271.5M. Net loss decreased 27% to $107.4M. Revenues reflect Royalty revenue increase of 41% to $2.2M. Lower net loss reflects Loss (Gain) in fair value of contingent decrease from $748K (expense) to $6.6M (income), Interest Expense - Net of Capitalized In decrease of 18% to $7.9M (expense).